Autolus Therapeutics PLC (NAS:AUTL)
$ 3.92 0.05 (1.29%) Market Cap: 1.04 Bil Enterprise Value: 335.67 Mil PE Ratio: 0 PB Ratio: 1.79 GF Score: 55/100

Autolus Therapeutics PLC Investor Meeting Transcript

Dec 10, 2023 / 04:00PM GMT
Rob Dolski Autolus Therapeutics plc;CFO

Good morning everyone, here San Diego and to those on our webcast, welcome to Autolus Therapeutics analyst and investor meeting to discuss the data that we presented yesterday, here at the (inaudible) I'm Rob Dolski, CFO of Autolus. With me today are Dr. Christian Itin, our Chief Executive Officer, and Professor Claire Roddie, Associate Professor Hematology and Honorary Consultant Hematologist, Cancer Institute, University College London.

As a reminder, before we begin, I just want to remind that during today's meeting, we will make statements related to our business that are forward-looking under federal securities laws and Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.

These include, but are not limited to statements regarding the status of clinical trials, development or regulatory timelines and expectations regarding our runway, our cash runway. These statements are subject to a variety of risks and uncertainties that could cause actual results to differ materially from expectations and reflect only our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot